MesaGreen Pharmaceutical Company Files an Investigational New Animal Drug Application
FREDERICK, MD. Nov. 10, 2022—MesaGreen Pharmaceutical Company announced today that the company has filed an Investigational New Animal Drug (INAD)…
FREDERICK, MD. Nov. 10, 2022—MesaGreen Pharmaceutical Company announced today that the company has filed an Investigational New Animal Drug (INAD)…
Mesa Science Associates Inc. (MSA) received a Phase I Small Business Innovative Research Grant (SBIR) from the National Institutes of…
Mesa Science Associates has applied for an NIH Small Business Innovative Research (SBIR) Grant from the National Institutes of Health…
Mesa Science Associates Inc. (MSA) and Mesa Green Pharma LLC (MGP) are pleased to announce the results of a study…
Pilot Study Provides Positive Results for K9MGP Treatment Active Canine Seizures FREDERICK, Md. September 21,2021— Mr. Michael Mesa, CEO of…
August 13, 2021 – This summer, I was able to intern for Mesa Science Associates (MSA). During my tireless search…
May 2021 This prestigious committee will review grant applications for Pre-doctoral, Post-doctoral and Research Starter Grants dealing with innovative approaches…
K9MGP Seizure Program In July 2019, MesaGreen Pharmaceutical (MGP) entered into a research agreement with the University of Minnesota Schools…
Mesa Science Associates is pleased to announce that Peyton Coady, a former intern at MSA will be graduating from James…
Our surviving the Covid-19 experience has been an example of what having a great team can do for a company….
FREDERICK, MD. Nov. 10, 2022—MesaGreen Pharmaceutical Company announced today that the company has filed an Investigational New Animal Drug (INAD)…
Mesa Science Associates Inc. (MSA) received a Phase I Small Business Innovative Research Grant (SBIR) from the National Institutes of…
Mesa Science Associates has applied for an NIH Small Business Innovative Research (SBIR) Grant from the National Institutes of Health…